Medtronic to Acquire Scientia Vascular for $550 Mn in Second Deal of 2026

The acquisition includes the potential for additional milestone payments, though the value of those payments was not disclosed.

Medtronic has agreed to acquire neurovascular technology company Scientia Vascular for $550 million, marking its second acquisition of 2026 as the company expands its portfolio of devices used in stroke and aneurysm treatment.

The acquisition includes the potential for additional milestone payments, though the value of those payments was not disclosed. Medtronic announced the agreement Tuesday, noting that Scientia’s devices are designed to help physicians navigate the brain’s complex vascular structures during neurovascular procedures.

Scientia Vascular develops access devices used in procedures treating conditions such as stroke and cerebral aneurysms. These tools are intended to support physicians in navigating the cerebral vascular system to reach blockages or aneurysm sites during minimally invasive interventions.

The proposed acquisition follows Medtronic’s February announcement that it would acquire CathWorks for up to $585 million, making the Scientia transaction the company’s second tuck-in acquisition of the year.

Scientia Vascular was founded in 2007 by John Lippert, who currently serves as the company’s chief technology officer. The company developed microfabrication technology aimed at addressing challenges in navigating the brain’s intricate vascular network, which can make it difficult for physicians to reach the site of an occlusion or aneurysm.

Originally based in Reno, Nevada, Scientia relocated to Salt Lake City, Utah, in 2013. The company currently employs around 310 people. Its first guidewire received clearance from the U.S. Food and Drug Administration in 2018.

Healthcare investment firm Vivo Capital invested $50 million in equity financing in the company in 2021 to support product development and expansion.

Medtronic said Scientia’s technologies enable faster and more reliable navigation during neurovascular procedures. According to Linnea Burman, president of Medtronic’s neurovascular business, the acquisition supports procedures addressing both hemorrhagic stroke and acute ischemic stroke.

The guidewire and catheter portfolio developed by Scientia is expected to integrate with Medtronic’s existing neurovascular product line, expanding the company’s tools used in a range of brain vascular interventions.

Medtronic said the transaction is expected to close in the first half of its fiscal year 2027, which typically ends in April. The company expects the deal to be minimally dilutive to adjusted earnings per share in fiscal 2027 and accretive thereafter.

Stay tuned for more such updates on Digital Health News